Burkhardt Joins PhyMed as VP of Business Development
NASHVILLE, TN — Jay Burkhardt, a healthcare executive with extensive experience in strategic planning and corporate development, has been named vice president of business development at PhyMed Healthcare Group, a physician-led and owned leader of anesthesia and pain management services. Burkhardt will be responsible for executing the company’s aggressive growth initiatives, with an emphasis on mergers and acquisitions.
Most recently, Burkhardt served in a strategic leadership role with McKesson Specialty Health and The US Oncology Network, where he led strategic planning for a division that both partners with and invests in independent specialty practices. Previously, he served in several other corporate development and strategy roles at McKesson where his responsibilities included sourcing, negotiating and executing transactions.
Burkhardt earned a master’s degree in International Management from Thunderbird School of Global Management and an MBA from Oklahoma State University. He has also completed the M&A; program at The Wharton School at The University of Pennsylvania. He earned his B.A. from DePauw University.
“Jay’s unique combination of experience will be a valuable asset to our growth efforts,” said Sami Abbasi, president and chief executive officer of PhyMed. “Jay’s background in business development and strategic planning fits well with our disciplined approach to market selection and expansion and our differentiated value proposition to like-minded, leading anesthesiology practices.”
“I am excited about this opportunity at PhyMed,” said Burkhardt. “The company has an outstanding reputation in the market and aggressive growth plans. I look forward to helping anesthesiology practices take advantage of all that PhyMed has to offer as they evolve their practice in a dynamic healthcare
environment.”
Press Releases
Read the latest news updates from within PhyMed.
Practice News
Read the latest news from our partner practices.
Media Hits
Read the latest media hits from PhyMed.